CYP2C19 polymorphism influences Helicobacter pylori eradication

Area of Science:

• Pharmacogenomics
• Gastroenterology
• Microbiology

Background:

• H. pylori eradication rates are declining due to factors like antibiotic resistance and CYP2C19 polymorphism.
• Proton pump inhibitors (PPIs) are key in H. pylori eradication regimens.
• CYP2C19 is the primary enzyme metabolizing many PPIs, with genetic variations affecting drug efficacy.

Purpose of the Study:

• To investigate the influence of CYP2C19 genetic polymorphism on H. pylori eradication rates.
• To determine the impact of CYP2C19 genotype on the efficacy of different PPI-based eradication therapies.
• To explore personalized medicine approaches for H. pylori eradication based on pharmacogenetics.

Main Methods:

• Review of existing literature on H. pylori eradication, PPI metabolism, and CYP2C19 genetics.
• Analysis of how CYP2C19 genotype affects PPI efficacy in various triple and rescue therapies.
• Consideration of ethnic variations in CYP2C19 polymorphism frequency.

Main Results:

• CYP2C19 genotype significantly impacts H. pylori eradication with omeprazole- or lansoprazole-based triple therapies.
• CYP2C19 polymorphism does not significantly affect eradication rates with rabeprazole- or esomeprazole-based triple therapies.
• The effect of CYP2C19 genotype on levofloxacin-based rescue therapy efficacy is variable.

Conclusions:

• Individualizing PPI selection and dosage based on a patient's CYP2C19 genotype and drug pharmacokinetics is essential for optimizing H. pylori eradication.
• Pharmacogenetic considerations, alongside other factors like IL-1β-511 polymorphism, are vital for successful H. pylori treatment.
• Personalized H. pylori eradication strategies can improve treatment outcomes and combat antibiotic resistance.